103 related articles for article (PubMed ID: 15572556)
1. Combination therapy with maintenance budesonide and formoterol in COPD.
Medford AR
Eur Respir J; 2004 Dec; 24(6):1070; author reply 1070-1. PubMed ID: 15572556
[No Abstract] [Full Text] [Related]
2. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Calverley PM; Boonsawat W; Cseke Z; Zhong N; Peterson S; Olsson H
Eur Respir J; 2003 Dec; 22(6):912-9. PubMed ID: 14680078
[TBL] [Abstract][Full Text] [Related]
3. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
[TBL] [Abstract][Full Text] [Related]
4. Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA; Perry CM; Keating GM
Drugs; 2004; 64(4):431-41; discussion 433-4. PubMed ID: 14969576
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
[TBL] [Abstract][Full Text] [Related]
6. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.
Centanni S; Di Marco F
Expert Opin Pharmacother; 2005 Nov; 6(14):2525-34. PubMed ID: 16259583
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
8. [Fixed combination of inhalant steroids and long-acting beta(2) agonists].
Petermann W; Mutschler E
Dtsch Med Wochenschr; 2004 Jan; 129(5):210-4. PubMed ID: 14735419
[No Abstract] [Full Text] [Related]
9. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease.
Cazzola M
Pulm Pharmacol Ther; 2006; 19(2):79-89. PubMed ID: 15964228
[TBL] [Abstract][Full Text] [Related]
10. [Combined inhaled corticosteroid and long-acting beta-2-agonist in one inhaler in the treatment of chronic obstructive pulmonary disease].
Pedersen ST
Ugeskr Laeger; 2005 Jun; 167(23):2504-6. PubMed ID: 16008004
[No Abstract] [Full Text] [Related]
11. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
12. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.
Tashkin DP
Expert Rev Respir Med; 2010 Dec; 4(6):703-14. PubMed ID: 21128746
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
[TBL] [Abstract][Full Text] [Related]
15. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
Ankerst J
J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864
[TBL] [Abstract][Full Text] [Related]
16. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
Aballéa S; Cure S; Vogelmeier C; Wirén A
Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
[TBL] [Abstract][Full Text] [Related]
17. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
Szmidt M
Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
[TBL] [Abstract][Full Text] [Related]
18. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
19. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
20. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma.
Murphy K; Nelson H; Parasuraman B; Boggs R; Miller C; O'Dowd L
Curr Med Res Opin; 2008 Mar; 24(3):879-94. PubMed ID: 18267051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
